

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Tice *et al.*

Application No.: 10/614,116

Filed: July 3, 2003

For: **Ketone Ligands for Modulating the
Expression of Exogenous Genes Via an
Ecdysone Receptor Complex**

Confirmation No.: 3335

Art Unit: 1633

Examiner: Popa, Ileana

Atty. Docket: 2584.0020001/RWE/RAS

Applicants' Summary of the Substance of an Interview

Attn: Mail Stop Issue Fee

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants note that an Interview Summary was mailed September 19, 2007 for the captioned application. Hence, in accordance with 37 C.F.R. §§ 1.2 and 1.133, and MPEP § 713.04, Applicants' undersigned representative provides the following statement of the substance of the interview held with the Examiner regarding the captioned application.

Applicants' representative telephoned the Examiner to point out that the Information Disclosure Statement filed June 26, 2007 had not been considered. The Examiner stated that she would consider the Information Disclosure Statement and send the initialed PTO-1449 forms to Applicants.

Applicants respectfully request that this statement be entered into the record. Further, it is not believed that extensions of time are required. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees

required therefor are hereby authorized to be charged to our Deposit Account No.
19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert A. Schwartzman, Ph.D.
Attorney for Applicants
Registration No. 50,211

Date: October 19, 2007

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600